Photodynamic Therapy for Chronic Central Serous Chorioretinopathy According to Degree of Choroidal Hyperfluorescence
Journal of the Korean Ophthalmological Society
;
: 268-275, 2012.
Article
in Korean
| WPRIM
| ID: wpr-9406
ABSTRACT
PURPOSE:
To compare the efficacy of photodynamic therapy (PDT) depending on the degree of hyperfluorescence based on indocyanine green angiography (ICGA) for treating chronic central serous chorioretinopathy (CSC).METHODS:
Twenty-three eyes of 23 patients with chronic CSC were recruited for the present study. The minimum follow-up period was six months. The total energy of PDT was reduced to 25 J/cm2 for 83 seconds. The baseline middle-phase ICGA findings were classified as intense or low hyperfluorescence depending on the degree of hyperpermeability from choriocapillaris. The change in mean best-corrected visual acuity, the resolution of subretinal fluid, recurrence rate, and complication were analyzed in relation to each ICGA finding at baseline.RESULTS:
The baseline ICGA findings showed intense hyperfluorescence in 11 eyes (47.8%) and low hyperfluorescence in 12 eyes (52.2%). The subretinal fluid resolved completely one month after a single application of low-fluence PDT in both groups. The subretinal fluid recurred in one of 12 eyes (8.3%) with low hyperfluorescence and in no eyes (0%) with intense hyperfluorescence. There was no statistically significant difference in the rate of recurrence between the two groups.CONCLUSIONS:
Low-fluence PDT appears to be an effective and safe treatment option for long-standing chronic CSC regardless of the degree of hyperfluorescence based on the ICGA.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Photochemotherapy
/
Recurrence
/
Triazenes
/
Angiography
/
Visual Acuity
/
Follow-Up Studies
/
Choroid
/
Eye
/
Central Serous Chorioretinopathy
/
Subretinal Fluid
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Ophthalmological Society
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS